In colitic mice, the formulation significantly reduced TNF-α mRNA (50%) and protein (45%) expression and ameliorated colitis symptoms reflected by the DAI, loss of body weight, colon length, MPO activity and histopathology. The gene discussed is TNF; the disease is colitis.